Conclusion: Our data demonstrate that an increase in INL volume is associated with MSON and the occurrence of clinical relapses. Therefore, INL volume changes may be useful as an outcome marker for inflammatory disease activity in MSON and MS treatment trials.
Introduction
Thinning of the inner retinal layers, as observed with the use of optical coherence tomography (OCT), is a common finding in multiple sclerosis (MS) patients. 1 Retinal OCT has been suggested as a structural imaging biomarker for neuroaxonal degeneration, as reduced thickness of both the peripapillary retinal nerve fibre layer (pRNFL, consisting of axons) and the combined thickness of the ganglion cell layer and inner plexiform layer (GCIPL, consisting of mainly ganglion cells) have shown to be associated with grey and white matter atrophy in patients with MS. [2] [3] [4] [5] [6] Although the association of pRNFL and GCIPL thickness with neurodegeneration in MS is well established, a more complex situation is observed for the adjoining inner nuclear layer (INL) . A histological study demonstrated that the INL, representing a neuronal network of bipolar, amacrine and horizontal cells, shows signs of atrophy but the presence of inflammatory cells was also described. 7 Nevertheless, the INL seems not to be susceptible to retrograde degeneration caused by MS-related optic neuritis (MSON), as it does not show the extensive neuro-axonal injury in eyes with MSON as observed in the pRNFL and GCIPL. 1, 8 Rather than reflecting neurodegeneration like the innermost pRNFL and GCIPL, the INL may rather be a biomarker for inflammatory processes. In 2012, Gelfand et al. first described the presence of microcystic macular oedema (MMO) in the INL and the relationship with disability. 9 Furthermore, a retrospective study by Saidha and colleagues reported that increased thickness of the combined INL and outer plexiform layer (OPL) was associated with disease activity in MS. 10 More recently, Knier et al. reported that successful use of disease-modifying treatment (DMT) is associated with sustained reduction of INL volume, 11 suggesting that the INL could serve as a biomarker to monitor central nervous system inflammation. Therefore, the aim of this study was to investigate the relationship of INL volume changes over time with local and global inflammatory disease activity in a large cohort of patients with MS.
Methods

Study design and participants
We used longitudinal data from the International Multiple Sclerosis Visual System Consortium (IMSVISUAL) database (www.imsvisual.org). Patients were recruited from 11 centres in the
, the United States (New York City N ¼ 10) and France (Lille N ¼ 72). Healthy control individuals (HCs) were recruited from three centres (Amsterdam N ¼ 41, Munich N ¼ 17 and Berlin N ¼ 34). All patients and HCs participated in local observational studies and provided written informed consent for participation in their respective studies. Data were pooled retrospectively. All data from reported and ongoing cohort studies at MS centres were stored in the IMSVISUAL repository. The raw dataset is available from IMSVISUAL on request.
Data were collected between 2010 and 2017. MS patients were included if they were between ages 16 and 80 years, and had a diagnosis of clinically isolated syndrome or MS (including relapsingremitting (RR), secondary progressive (SP) and primary progressive (PP) subtypes) according to the revised 2010 McDonald Criteria. 12 HCs were included if they were between ages 18 and 80 years and had no history of any neurological disease or ophthalmologic reason for retinal pathology. Regarding the OCT assessments, individuals were included if they had at least two OCT measurements (baseline and at least one follow-up) with INL volume available for at least one eye (minimum follow-up period of six months). Patients were excluded if they had experienced symptomatic MSON within six months preceding the OCT assessment (baseline or followup), or if history of MSON was ambiguous or unknown. Inclusion and exclusion of individuals is shown in the flowchart in Figure 1 .
OCT
Retinal OCT was performed at each centre by use of spectral-domain OCT with Spectralis (Heidelberg Engineering, Heidelberg, Germany, N ¼ 10) or OCT-2000 (Topcon Corp, Itabashi, Japan, N ¼ 1). Data on the INL and GCIPL volume (mm 3 ) in the macular area were acquired using a macular volume scan centred on the fovea, using a 6 mm ring area. Data on global pRNFL thickness (mm) were obtained using a 12-degree ring scan (corresponding to a 3.4 mm diameter) manually placed around the optic disc. At each centre, automated segmentation of OCT scans and quality control (including the assessment whether eyes had signs of MMO) were performed. 13, 14 Importantly, the scanning device and protocols were kept identical for all longitudinal measurements within each centre. 15 Clinical and ophthalmological outcome measures Demographic data included data on sex, age at baseline and disease duration (from disease onset). Clinical data were collected longitudinally and included MS subtype, occurrence of relapses between visits, Expanded Disability Status Scale (EDSS) score, history of previous MSON and occurrence of new episodes of MSON between visits, presence of MMO and use of DMT. The assessment of history of symptomatic MSON (based on medical history, according to a standard protocol), 16 EDSS score and data on clinical relapses were provided by the individual centres.
Importantly, given the longitudinal design of this study, we made a clear distinction between episodes of MSON before the study (referred to as 'pre-study MSON') and episodes of MSON during the followup of the study (referred to as 'MSON during follow-up').
EDSS assessment was performed by a certified examiner and in the absence of acute relapses. Disability progression was defined by an increase in EDSS score of 1.0 point in case EDSS score was less than 5.5 at baseline, or an increase of 0.5 if EDSS score was 5.5 or greater at baseline. This approach is consistent with previous IMSVISUAL collaborative projects. 17 
Statistical analyses
Annualised changes in retinal layer thickness or volume were calculated for every follow-up period. Subsequently, the annualised change scores were averaged over the complete observation period, resulting in one average annualised rate of change for every eye. All analyses were therefore performed on eye level, using generalised estimation equation (GEE) models with a correlation matrix structure that treats the eye measurements as exchangeable to adjust for intra-subject inter-eye dependency. 15 All GEE models were additionally adjusted for relevant confounders (baseline OCT value, pre-study episodes of MSON, disease duration, use of DMT) as indicated. Figures showing longitudinal changes in retinal layer thickness were produced using relative annualised change scores (i.e. baseline was set as 100%).
Regarding the associations between annualised change in retinal thickness and the occurrence of relapses or disease progression, all eyes with a history of MSON were excluded. Short-term effects (clinical event and retinal change assessed within same follow-up period) as well as longterm effects (time-lag analyses, clinical event between baseline and first follow-up visit and change in retinal layer thickness between first and second follow-up visit) were investigated. Consequently, only individuals with at least three visits were included in these analyses. All analyses were adjusted for their respective baseline retinal layer thickness.
Correlations between the different layers were calculated with standardised regression coefficients in GEE models and are therefore also adjusted for inter-eye dependency. Statistical analyses were performed using SPSS V.22.0 (IBM Corp, Armonk, NY, USA) and Stata V.14.1 (StataCorp LP, College Station, TX, USA) with a two-sided statistical significance level of .05. Figure 1 . Flowchart of study design. Of the 903 individuals in the initial database, 785 patients and 92 healthy controls were included in this study. All participants had at least two visits, and a subset also had a third or fourth visit. Longitudinal data on inner nuclear layer (INL) and ganglion cell-inner plexiform layer (GCIPL) volume (at least two visits, minimum follow-up >6 months) was available for all included individuals and peripapillary retinal nerve fibre layer (pRNFL) for 765 patients and 91 healthy controls. IMSVISUAL: International Multiple Sclerosis Visual System Consortium; MS: multiple sclerosis; MSON: multiple sclerosis optic neuritis. , respectively, p ¼ .001), whereas GCIPL volume and pRNFL thickness alike were lower in eyes with pre-study MSON compared with eyes without (Table 2) .
Change over time in INL, GCIPL and pRNFL thickness and the effect of MSON The median follow-up duration was 2.1 years (range, 0.5 to 5.2 years) for MS patients and 2.0 years (range, 0.6 to 4.6 years) for HCs. When all eyes of MS patients were analysed together, the INL showed Figure 2(b) ). Exclusion of patients with a progressive disease type, or adjustments for use of DMT, disease duration or participating centre, did not change these results (data not shown). The annualised rate of change for GCIPL in MS patients was -0.012 mm 3 (p < .001), which was significantly more than observed in HCs (-0.004 mm 3 , p ¼ 0.116, p value for comparison .008). The pRNFL showed significantly more thinning in MS patients (-0.97 mm, p < .001) compared with HCs (-0.42 mm, p < .001, p value for comparison .001, Figure 2(a) ). For both layers, eyes with episodes of MSON during the follow-up period showed significantly more thinning than unaffected eyes (Figure 2(b) ). Table 3 demonstrates the effects of new episodes of MSON during follow-up, other clinical relapses and disease progression on annualised change in INL and GCIPL volume and pRNFL thickness. The short-term (clinical event and retinal change assessed within the same follow-up period, Table 3(a)) as well as the long-term (time-lag analyses, clinical event between t0 and t1 and change in retinal layer thickness between t1 and t2, Table 3(b)) effects are reported. The median duration of t0-t1 was 1.1 year (IQR 1.0-1.9) and for t1-t2 the median duration was 1.0 year (IQR 1.0-1.7).
Short-and long-term effects of clinical disease activity on retinal layer thickness
Clinical episodes of MSON during follow-up demonstrated only a short-term effect on INL (thickening) and GCIPL and pRNFL (thinning). In the time-lag analyses investigating the long-term effects, these effects disappeared. Exclusion of patients with a progressive disease course did not change the statistical findings.
Clinical relapses (other than MSON) during followup were present in 24.4% of patients. The occurrence of clinical relapses during the first follow-up was not related to change in INL within the same Table 3 (a)).
Disability progression was observed in 17.2% (during the entire follow-up period). Annualised change in INL volume was independent of disability progression both in the short and long term. Likewise, disability progression was not significantly associated with annualised changes in GCIPL or pRNFL (Table 3 (a) and 3(b)).
Effect of MMO, disease type and DMT on retinal changes
In the 1.4% of eyes with MMO before or during the study (18/ Just more than half the patients (53.8%) used DMT during the study. Although the annualised change in INL volume was not influenced by use of DMT, the absolute INL volume was significantly higher in patients using fingolimod compared with RRMS patients who did not use any DMT, independent of history of pre-study MSON and MMO, EDSS at baseline and disease duration (difference 0.03 mm 3 , p ¼ .004). Other therapies did not show significant differences in INL volume.
Interrelationship between layers
All analyses regarding the interrelationships between the layers demonstrated effect modification by presence of a new episode of MSON during follow-up and are therefore stratified. In eyes with MSON during follow-up, an increase in INL volume was related to a decrease in GCIPL volume (standardised b ¼ -0.42, p ¼ .006, black line in Supplementary Figure 1(a) ) and to a lesser extent (although not statistically significant) to a decrease in pRNFL (standardised b ¼ -0.15, p ¼ .148, black line in Supplementary  Figure 1(b) ). In eyes without new MSON, no significant association with change in INL volume was observed (grey lines in Supplementary Figures 1(a)  and (b) ). In contrast, GCIPL and pRNFL show positive correlations both in eyes with new MSON (standardised b ¼ 0.41, p < .001) and without MSON (standardised b ¼ 0.26, p ¼ .004, see Supplementary  Figure 1(c) ).
Discussion
This longitudinal, multi-centre study demonstrates that thickening of the INL as measured with spectral-domain OCT reflects adjacent inflammation of the optic nerve. Besides this association with local inflammation, the INL seems to reflect some degree of global disease activity, as the occurrence of clinical relapses in any functional system was significantly associated with a subsequent increase in INL volume. However, this effect was relatively small (difference of 0.005 mm 3 ) and should be interpreted with caution, as the sensitivity might be limited.
These findings build on previous findings from other studies, demonstrating the relationship between thickening of the INL and physical disability 9 and disease activity. 10 Saidha et al. 10 reported that INL/ OPL thickening at baseline was predictive of clinical relapses, new T2 and contrast-enhancing lesions on magnetic resonance imaging and disability progression during follow-up. In contrast, in the present study we did not observe any predictive value of INL thickening on clinical relapses or disability progression. Our data demonstrated an association between INL volume and clinical relapses only in the time-lag model, in which clinical relapses preceded INL thickening. This would suggest that INL thickening occurred subsequent to inflammatory disease activity. A predictive effect of baseline INL volume on the occurrence of relapses or disability progression, as described by Saidha and colleagues, 10 was not observed in the present study.
When thickening of the INL was first described, it was directly linked to the presence of MMO. 9 Although MMO is present in MS and is related to increased disability, 9, 10, 18 it is not specific for MS and may vary over time in individual patients. 19, 20 Importantly, we have previously demonstrated that MMO was transient in 84% of cases. 19 In the present study, MMO was present in 2.4% of patients, which is consistent with previous findings. [9] [10] [11] 21 In the present study we observed increased INL volume in eyes with MMO, which is also consistent with existing literature. 1 Moreover, eyes with MMO also showed a significant increase in INL volume over time. Nevertheless, the findings of the present study did not change when MMO eyes were excluded, suggesting that thickening of the INL can occur in the absence of visually detectable MMO.
The underlying mechanism responsible for thickening of the INL remains unknown. The findings of this study would imply that previously suggested mechanisms such as inflammation-related dynamic fluid shifts and Müller cell dysfunction are more likely than other non-inflammatory mechanisms such as traction and retrograde trans-synaptic degeneration. 21, 22 Dynamic retinal layer volume changes can be explained by fluid shifts due to a combination of osmotic and hydrostatic gradients, the retinal glymphatic system. [23] [24] [25] [26] The INL is embedded between the superficial vascular plexus and the deep capillary plexus, which can be clearly visualised on OCT angiography. 24 Typically, fluid reaches the retina through the internal limiting membrane and both plexuses, whereas both plexuses and Müller cells can absorb the interstitial fluid. In case of inflammation, diffusion of fluid from the retinal blood vessels increases, leading to an increase in INL volume. Another suggested mechanism is pathology of Müller cells, which would impair the absorption of interstitial fluid, also resulting in increased INL volume. Other suggested noninflammatory mechanisms such as traction or retrograde trans-synaptic degeneration are also plausible but less well supported by our data, given the clear and direct increase in INL volume following MSON. One approach to further elucidate the underlying mechanism would be the investigation of the retinal vessels using OCT angiography.
Previously, we and others have described the limited susceptibility of the INL to retrograde degeneration caused by MSON.
1 This is in line with our current findings, in which the pRNFL and GCIPL clearly showed significant thinning in eyes with previous episodes of MSON, whereas for the INL no thinning but rather an increase in volume was observed. The opposing effects of local inflammation on the INL on the one hand and pRNFL/GCIPL on the other are clearly demonstrated by the negative correlation between the layers. This further substantiates the potential of pRNFL/GCIPL as a measure for neurodegeneration, whereas INL volume may be a valuable parameter for reflecting inflammatory activity.
A recent study by Knier et al. reported that effective treatment with DMT in patients with MS is associated with a sustained reduction in INL volume in the absence of MSON, and they suggested that INL volume may be a response marker for successful treatment of inflammation. 11 Building on these findings, we investigated the effect of DMT on INL volume changes. Although the absolute INL volume was significantly higher in patients using fingolimod compared with RRMS patients who did not use any DMT, which corroborates previous findings on retinal effects of this drug, 27 ,28 the annualised change in INL volume was not influenced by use or type of DMT. However, it should be noted that DMT data were available only at baseline for the majority of patients, and that data on the exact duration of treatment or previous DMTs were not available. This lack of detailed information did not permit a thorough investigation of direct effects of DMT or replication of previous results.
Another limitation of the study was that the data did not permit the determination of how acute new episodes of MSON were. A systematic assessment of the early time course of acute MSON would be extremely valuable, and there will need to be a consensus as to what will be defined as onset of an acute episode of MSON. Furthermore, disease activity was recorded only by clinical relapse activity. Data on radiological disease activity (new T2 and/or gadolinium-enhancing lesions during follow-up) were not available. Therefore, no conclusions could be made regarding the relationship of INL volume and radiological disease activity. A common limitation of multi-centre studies is the difference in methodology among the participating centres. 29, 30 The OCT device and software were the same for all centres (Spectralis) but one (Topcon). The data on retinal layer thickness of this particular centre were not significantly different from the other centres', and additional adjustment for a potential centre effect did not change any of the results (data not shown).
In summary, our data demonstrate that an increase in INL volume is strongly associated with inflammation of the optic nerve, and to a lesser degree with other clinical relapses. Therefore, INL volume may be a valuable parameter for capturing inflammatory Multiple Sclerosis Journal-Experimental, Translational and Clinical disease activity and may be considered as an outcome measure for MS and MSON treatment trials.
